Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

Third Capital Markets Day – STADA commits to Russian market in Saint Petersburg

  • 15/09/2015
  • Press Release

Bad Vilbel/Saint Petersburg, September 15, 2015 – For the third time, STADA Arzneimittel AG invited investors and analysts to a Capital Markets Day. This year, the focus of the event was on STADA's engagement in Russia. In St. Petersburg, the Executive Board and the Russian Management Board provided insights into the potentials and characteristics of the Russian market and highlighted the importance of Russia as a commercial location for STADA. After the event, Hartmut Retzlaff, Chairman of the Executive Board, concluded: "Despite all the challenges that we have been faced with in our market region CIS/Eastern Europe during the last few months, we continue to build on our business activities in Russia and are convinced of its long-term potential".

Helmut Kraft, Chief Financial Officer at STADA, added: "STADA is very well positioned with its convincing portfolio and a modern GMP production. In light of this, we expect to achieve double digit percentage growth in sales in local currency in the Russian market in financial year 2015 and, in the medium term, to emerge from the crisis as a strengthened company." At the event, Aleksey Alekhin, Deputy Director of Pharmaceutical and Medical Industry Development Department Russian Ministry for Industry and Trade, emphasized the attractiveness of the country in general and of the pharmaceutical sector for foreign investors in particular.

STADA's Senior Vice President Dmitry Efimov, who has been responsible for the market regions CIS/Eastern Europe since 2012 and is also the CEO of STADA's subsidiary Nizhpharm, then presented critical success factors in connection with the Russian umbrella label STADA CIS: "Not least thanks to our extraordinary sales network and a well-balanced product portfolio, we have become the number seven company in the Russian pharmaceutical market and the number two among local producers". Despite the economic situation, STADA CIS achieved convincing results in Russia in the first half of 2015: Compared with the overall market in ruble, which increased by 11.1 percent as compared to the previous year, the sales of the Russian STADA subsidiary more than doubled with 23.4 percent.

STADA has been active in the Russian market for about ten years now. In financial year 2014, the Group achieved sales in Russia in the amount of Euro 360.7 million and employed 2,343 in the country.
All of the presentations shown at the Capital Markets Day are available on STADA's website under Investor Relations at www.stada.com/cmd2015.